Portola Pharmaceuticals
Portola Pharmaceuticals was a South San Francisco-based biopharmaceutical company that developed andexanet alfa (Andexxa), a first-in-class FDA-approved reversal agent for Factor Xa inhibitor anticoagulants, serving hospital emergency departments and trauma centers treating patients with life-threatening bleeding.
- Company typePrivate
- Founded2003
- HeadquartersSouth San Francisco, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Portola Pharmaceuticals does
Portola Pharmaceuticals is a clinical-stage and commercial-stage biopharmaceutical company founded in 2003 and headquartered in South San Francisco, California. The company developed therapeutics targeting acute and chronic cardiovascular, autoimmune, and inflammatory diseases, with its primary commercial focus on anticoagulation reversal. Portola's lead product was andexanet alfa (marketed as Andexxa), a first-in-class specific reversal agent for Factor Xa inhibitors rivaroxaban and apixaban — direct oral anticoagulants (DOACs) whose use had expanded rapidly, creating an unmet need for emergency bleeding reversal in hospitals and trauma centers. Andexxa's mechanism targeted life-threatening bleeding complications in patients on these anticoagulants, positioning the drug as a critical hospital formulary product for emergency departments.
The company's business model centered on developing, obtaining FDA approval for, and commercializing specialty biologics through hospital-based sales channels targeting emergency medicine, trauma surgery, and hematology prescribers. Portola funded its operations through a multi-decade series of venture, public equity, and non-dilutive royalty financings totaling over $1.3 billion across more than a dozen rounds from 2003 through 2019, including a $349.25M round in 2017 and a $125M royalty financing with Athyrium Capital and HealthCare Royalty Partners in 2019. The company was acquired by AstraZeneca, which absorbed Portola's assets including Andexxa into its portfolio. As of December 2025, AstraZeneca announced plans to voluntarily withdraw Andexxa from the U.S. market following FDA determination that thromboembolic risks outweighed benefits, ending Portola's commercial franchise.
Portola's organizational footprint was modest (51-100 employees pre-acquisition), reflecting the lean structure typical of single-asset specialty biotechs. The leadership team included Scott Garland as President & CEO, Charles Homcy as Chairman of the Board, Ernie Meyer as CHRO, and Glenn Brame as EVP & Chief Technical Officer. The company was publicly traded on NASDAQ under ticker PTLA prior to its acquisition.
Portola Pharmaceuticals firmographics
Firmographics- Name
- Portola Pharmaceuticals
- Legal name
- Alexion Pharmaceuticals, Inc.
- Website
- https://portola.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Portola Pharmaceuticals was a South San Francisco-based biopharmaceutical company that developed andexanet alfa (Andexxa), a first-in-class FDA-approved reversal agent for Factor Xa inhibitor anticoagulants, serving hospital emergency departments and trauma centers treating patients with life-threatening bleeding.
- Ownership category
- akta.pro rank
Portola Pharmaceuticals industry classification
Industry- Product category
- Specialty Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor) (HLAIAHAF)
Keywords
Where Portola Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
Portola Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Portola Pharmaceuticals product offering
Product offeringCore offering
Portola Pharmaceuticals develops therapeutics for acute and chronic cardiovascular, autoimmune, and inflammatory diseases. Its flagship product Andexxa (andexanet alfa) is a specific reversal agent approved for use in patients experiencing life-threatening bleeding while taking Factor Xa inhibitor anticoagulants such as rivaroxaban and apixaban. The company sells its products to hospitals, emergency departments, and trauma centers requiring rapid anticoagulation reversal.
Differentiator
Problem solved
Functional benefit
Products and services
- Andexxa (andexanet alfa)
Companies that use Portola Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Portola Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Portola Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AstraZenecacoreAstraZeneca acquired Portola Pharmaceuticals' assets including Andexxa (andexanet alfa). AstraZeneca announced plans in December 2025 to withdraw Andexxa from the U.S. market following FDA safety concerns regarding thromboembolic risks. The FDA indicated that the risks outweigh the benefits, leading to voluntary withdrawal despite AstraZeneca's confidence in the drug's benefit-risk profile.
Recent moves6 records
Expansion highlights2 records
Portola Pharmaceuticals competitors and assessment
Company assessmentOthers
- Bayer: Bayer markets Xarelto (rivaroxaban), another leading Factor Xa inhibitor reversed by Andexxa. Bayer is a key originator of DOACs whose installed patient base drives demand for Portola's reversal agent.
- Pfizer: Pfizer co-markets Eliquis (apixaban) with BMS, one of the leading Factor Xa inhibitors reversed by Andexxa. Pfizer's commercial footprint and DOAC strategy shape the size and dynamics of Portola's downstream reversal market.
- Daiichi Sankyo: Daiichi Sankyo markets Savaysa (edoxaban), another Factor Xa inhibitor. As a DOAC originator, Daiichi Sankyo's franchise affects the addressable patient population for Portola's reversal agent.
- Boehringer Ingelheim: Boehringer Ingelheim markets Pradaxa (dabigatran), a direct thrombin inhibitor. Although Pradaxa is not a Factor Xa inhibitor, BI is a major originator of DOACs and a relevant competitor in the broader anticoagulation landscape Portola serves.
- Bristol-Myers Squibb: BMS co-markets Eliquis (apixaban), one of the DOACs that Andexxa reverses. While not a direct product competitor, BMS is a key stakeholder in the anticoagulant reversal market that defines Portola's addressable opportunity.
- Johnson & Johnson: Johnson & Johnson co-markets Xarelto (rivaroxaban) with Bayer. As a co-owner of one of the largest DOAC franchises, J&J shapes the volume of patients requiring Factor Xa inhibitor reversal therapy.
Broad incumbents
- AstraZeneca: AstraZeneca acquired Portola's assets, including Andexxa, and now controls commercialization decisions. As a global biopharmaceutical company with deep hospital and cardiovascular portfolios, AstraZeneca is the most consequential strategic peer for Portola post-acquisition.
- Takeda Pharmaceutical: Takeda has a significant specialty and rare disease biologic portfolio, including plasma-derived therapies, and operates in the hospital-administered specialty therapeutics space. Its global infrastructure and focus on cardiovascular and inflammatory disease overlap with Portola's therapeutic areas.
- Alexion Pharmaceuticals: Alexion is AstraZeneca's rare disease business unit and is referenced in Portola's company data following the AstraZeneca acquisition of Portola assets. Both focus on specialty/rare therapeutics with hospital-channel distribution, making Alexion a directly relevant comparator for Portola's biologics commercialization model.
Direct peers
- CSL Behring: CSL Behring is a leading plasma-derived and recombinant biologic therapeutics company. While not a direct competitor in DOAC reversal, it operates in adjacent hospital-administered specialty biologics and shares Portola's specialty biologics commercialization profile.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Portola Pharmaceuticals social profiles
Digital presencePortola Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Portola Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles4 records
Portola Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds12 records
Investors26 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Portola Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Portola Pharmaceuticals
What does Portola Pharmaceuticals do?
Portola Pharmaceuticals develops therapeutics for acute and chronic cardiovascular, autoimmune, and inflammatory diseases. Its flagship product Andexxa (andexanet alfa) is a specific reversal agent approved for use in patients experiencing life-threatening bleeding while taking Factor Xa inhibitor anticoagulants such as rivaroxaban and apixaban. The company sells its products to hospitals, emergency departments, and trauma centers requiring rapid anticoagulation reversal.
Is Portola Pharmaceuticals a public or private company?
Portola Pharmaceuticals is a private company. It is classified as public and is currently operating.
When was Portola Pharmaceuticals founded?
Portola Pharmaceuticals was founded in 2003. It employs 51 to 100 people.
Where is Portola Pharmaceuticals based?
Portola Pharmaceuticals is headquartered in South San Francisco, United States, in the North America region.
Who are Portola Pharmaceuticals's main competitors?
Others on record are Bayer, Pfizer, Daiichi Sankyo, Boehringer Ingelheim, Bristol-Myers Squibb and Johnson & Johnson. Broad incumbents are AstraZeneca, Takeda Pharmaceutical and Alexion Pharmaceuticals. CSL Behring is listed as a direct peer.
Does Portola Pharmaceuticals have an API?
No public API is recorded for Portola Pharmaceuticals.
What industry is Portola Pharmaceuticals in?
Portola Pharmaceuticals's product category is Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAIAHAF, Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor). Its NAICS code is 325412 and its SIC code is 2834.